Reported 4 months ago
Johnson & Johnson (J&J) has submitted applications for expanded approval of its HIV-1 therapy, PREZCOBIX (darunavir/cobicistat), in children aged six years and above. The company is seeking approval for use in pediatric patients weighing a minimum of 25kg, with applications filed in the US and Europe. A new pediatric formulation with a lower dose tablet has been developed, supported by clinical study data, to offer a treatment option for young people with HIV.
Source: YAHOO